PCMC
LCTX icon

Planning Capital Management Corporation’s Lineage Cell Therapeutics LCTX Stock Holding History

Planning Capital Management Corporation’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$996 Hold
1,100
– – ﹤0.01% 630
2024
Q2 		$1.1K Buy
1,100
+1,000
+1,000% +$1.1K ﹤0.01% 581
2024
Q1 		$148 Hold
100
– – ﹤0.01% 647
2023
Q4 		$109 Buy
+100
New +$110 ﹤0.01% 641

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Planning Capital Management Corporation's LCTX Position: Q3 2024 in Review

Planning Capital Management Corporation held its Lineage Cell Therapeutics (LCTX) position steady in Q3 2024 at 1,100 shares worth $996. The position accounts for ﹤0.01% of the portfolio, ranked #630.

Planning Capital Management Corporation first reported a position in LCTX in Q4 2023 and has held it in 4 quarters since. The position peaked at $1.1K in Q2 2024. 114 funds tracked by Wall St. Rank hold LCTX as of Q3 2024.

  • Planning Capital Management Corporation held 1,100 shares of Lineage Cell Therapeutics worth $996 as of Q3 2024.
  • Planning Capital Management Corporation left its Lineage Cell Therapeutics share count unchanged in Q3 2024.
  • Lineage Cell Therapeutics made up ﹤0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #630 holding.
  • Planning Capital Management Corporation first reported a position in Lineage Cell Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • Planning Capital Management Corporation's Lineage Cell Therapeutics position peaked at $1.1K in Q2 2024.
  • 114 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.